Corcept Therapeutics (CORT) Total Non-Current Liabilities (2017 - 2026)

Corcept Therapeutics has disclosed Total Non-Current Liabilities across 10 years of filings, most recently posting $161.6 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $161.6 million, up 8.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $161.6 million (up 8.49% YoY), and the FY2025 annual result was $173.7 million, up 18.24% from the prior year.
• Total Non-Current Liabilities came in at $161.6 million for Q1 2026 at Corcept Therapeutics, down from $173.7 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $177.6 million in Q3 2025 to a low of $49.1 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $106.4 million (2024), against an average of $113.3 million.
• Across the five-year window, Total Non-Current Liabilities rose 8.05% in 2022 and jumped 129.65% in 2023, its largest moves.
• Corcept Therapeutics' Total Non-Current Liabilities stood at $72.5 million in 2022, then soared by 44.16% to $104.5 million in 2023, then jumped by 40.55% to $146.9 million in 2024, then grew by 18.24% to $173.7 million in 2025, then declined by 6.97% to $161.6 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $161.6 million (Q1 2026), $173.7 million (Q4 2025), and $177.6 million (Q3 2025), per Business Quant data.